Runx2 in normal tissues and cancer cells: A developing story

被引：82

作者：

Blyth, Karen ^{[1
]}

Vaillant, Francois ^{[2
]}

Jenkins, Alma ^{[2
]}

McDonald, Laura ^{[1
]}

Pringle, Marie Anne ^{[3
]}

Huser, Camille ^{[3
]}

Stein, Torsten ^{[3
]}

Neil, James ^{[2
]}

Cameron, Ewan R. ^{[2
]}

机构：

[1] Beatson Inst Canc Res, Glasgow G61 1BD, Lanark, Scotland

[2] Univ Glasgow, Inst Comparat Med, Fac Vet Med, Glasgow G61 1QH, Lanark, Scotland

[3] Univ Glasgow, Div Canc Sci & Mol Pathol, Glasgow G11 6NT, Lanark, Scotland

来源：

BLOOD CELLS MOLECULES AND DISEASES | 2010年 / 45卷 / 02期

关键词：

Runx; Haematopoietic; Mammary; Prostate; Oncogene; ACUTE MYELOID-LEUKEMIA; TRANSCRIPTION FACTOR RUNX2; MAMMARY EPITHELIAL-CELLS; GENE-EXPRESSION; BREAST-CANCER; IN-VIVO; OSTEOBLAST DIFFERENTIATION; STEM-CELLS; SURVIVIN EXPRESSION; ADULT HEMATOPOIESIS;

D O I：

10.1016/j.bcmd.2010.05.007

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The Runx transcription factors are essential for mammalian development, most notably in the haematopoietic and osteogenic lineages. Runx1 and its binding partner, CBF beta,, are frequently targeted in acute leukaemia but evidence is accumulating that all three Runx genes may have a role to play in a wider range of cancers, either as tumour promoters or tumour suppressors. Whilst Runx2 is renowned for its role as a master regulator of bone development we discuss here its expression pattern and putative functions beyond this lineage. Furthermore, we review the evidence that RUNX2 promotes neoplastic development in haematopoietic lineages and in advanced mammary and prostate cancer. (C) 2010 Elsevier Inc. All rights reserved.

引用

页码：117 / 123

页数：7

共 76 条

[1] Reduction of runx1 transcription factor activity up-regulates Fas and Bim expression and enhances the apoptotic sensitivity of double positive thymocytes
Abe, N
Kohu, K
Ohmori, H
Hayashi, K
Watanabe, T
Hozumi, K
Sato, T
Habu, S
Satake, M
[J]. JOURNAL OF IMMUNOLOGY, 2005, 175 (07) : 4475 - 4482
[2] The leukemic protein core binding factor β (CBFβ)-smooth-muscle myosin heavy chain sequesters CBFα2 into cytoskeletal filaments and aggregates
Adya, N
Stacy, T
Speck, NA
Liu, PP
[J]. MOLECULAR AND CELLULAR BIOLOGY, 1998, 18 (12) : 7432 - 7443
[3] Runx2 association with progression of prostate cancer in patients: mechanisms mediating bone osteolysis and osteoblastic metastatic lesions
Akech, J.
Wixted, J. J.
Bedard, K.
van der Deen, M.
Hussain, S.
Guise, T. A.
van Wijnen, A. J.
Stein, J. L.
Languino, L. R.
Altieri, D. C.
Pratap, J.
Keller, E.
Stein, G. S.
Lian, J. B.
[J]. ONCOGENE, 2010, 29 (06) : 811 - 821
[4] AML1/ETO-induced survivin expression inhibits transcriptional regulation of myeloid differentiation
Balkhi, Mumtaz Yaseen
Christopeit, Maximilian
Chen, Yong
Geletu, Mulu
Behre, Gerhard
[J]. EXPERIMENTAL HEMATOLOGY, 2008, 36 (11) : 1449 - 1460
[5] Prolonged exposure to reduced levels of androgen accelerates prostate cancer progression in Nkx3.1; Pten mutant mice
Banach-Petrosky, Whitney
Jessen, Walter J.
Ouyang, Xuesong
Gao, Hui
Rao, Jayashree
Quinn, John
Aronow, Bruce J.
Abate-Shen, Cory
[J]. CANCER RESEARCH, 2007, 67 (19) : 9089 - 9096
[6] Fidelity of Runx2 activity in breast cancer cells is required for the generation of metastases-associated osteolytic disease
Barnes, GL
Hebert, KE
Kamal, M
Javed, A
Einhorn, TA
Lian, JB
Stein, GS
Gerstenfeld, LC
[J]. CANCER RESEARCH, 2004, 64 (13) : 4506 - 4513
[7] Barnes GL, 2003, CANCER RES, V63, P2631
[8] Runx2 and MYC collaborate in lymphoma development by suppressing apoptotic and growth arrest pathways in vivo
Blyth, K
Vaillant, F
Hanlon, L
Mackay, N
Bell, M
Jenkins, A
Neil, JC
Cameron, ER
[J]. CANCER RESEARCH, 2006, 66 (04) : 2195 - 2201
[9] Runx2:: A novel oncogenic effector revealed by in vivo complementation and retroviral tagging
Blyth, K
Terry, A
Mackay, N
Vaillant, F
Bell, M
Cameron, ER
Neil, JC
Stewart, M
[J]. ONCOGENE, 2001, 20 (03) : 295 - 302
[10] The RUNX genes: Gain or loss of function in cancer
Blyth, K
Cameron, ER
Neil, JC
[J]. NATURE REVIEWS CANCER, 2005, 5 (05) : 376 - 387

← 1 2 3 4 5 6 7 8 →